中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (6): 428-437.DOI: 10.12337/zgkqjxjyzz.2025.06.008

• 病例报告 • 上一篇    下一篇

高危险型黏膜类天疱疮的个体化治疗1例

任爽, 林菲然, 王红健, 付洁, 刘瑶, 任倩, 关晓兵*   

  1. 首都医科大学附属北京口腔医院黏膜科
  • 出版日期:2025-11-30 发布日期:2025-11-30
  • 通讯作者: *关晓兵,联系方式:010-57099246,电子邮箱:guanxbing2013@qq.com,通讯地址:北京市丰台区樊家村路9号,100070

A Case of High-Risk Mucous Membrane Pemphigoid with Individualized Treatment

Shuang Ren, Feiran Lin, Hongjian Wang, Jie Fu, Yao Liu, Qian Ren, Xiaobing Guan*   

  1. Department of Oral Medicine, Beijing Stomatological Hospital, Capital Medical University, Beijing, P.R. China
  • Online:2025-11-30 Published:2025-11-30
  • Contact: Xiaobing Guan. Tel: 010-57099246. Email: guanxbing2013@qq.com. Address: No.9 Fanjiacun Road, Fengtai District, Beijing 100070, P.R. China.

摘要: 目的:本文报道1例累及口腔和眼部的黏膜类天疱疮患者的诊疗过程,探讨高危险型黏膜类天疱疮的多学科协作诊治策略及阶梯式个体化的治疗方案。诊治经过:患者因“双眼充血、视力模糊”,于眼科就诊,建议口腔黏膜科排除黏膜类天疱疮,追溯病史发现患者2年前出现牙龈充血,未予治疗。经临床检查、组织病理学检查及直接免疫荧光学检查最终确诊为黏膜类天疱疮。治疗上采用全身糖皮质激素联合免疫抑制剂的阶梯方案,并贯穿于口腔科与眼科、内分泌科的多学科协作管理。结果:经过13个月治疗,患者口腔病损完全缓解,眼部活动性炎症得到有效控制,睑球粘连稳定未进展,全身激素顺利减量至维持剂量6mg/d,,为后续眼部手术创造了条件。结论:对于高危险型黏膜类天疱疮,早期精准诊断是前提,以全身免疫抑制为核心、多学科共同参与的个体化阶梯治疗是控制病情、阻止瘢痕形成和改善预后的关键。

关键词: 黏膜类天疱疮, 眼瘢痕性类天疱疮, 多学科团队协作, 糖皮质激素, 免疫抑制剂, 个体化治疗

Abstract: Objective: This case report describes the diagnosis and treatment process of a patient with mucous membrane pemphigoid (MMP) involving both oral and ocular regions, aiming to explore the multidisciplinary collaborative diagnosis and treatment strategy and the clinical outcomes of a stepped, individualized treatment regimen for high-risk MMP. Diagnosis and Treatments: The patient visited the Ophthalmology Department due to ‘congestion in both eyes and blurred vision’. He was advised to consult the Department of Oral Mucosa to rule out mucous membrane pemphigoid. A review of the medical history revealed that the patient developed gingival hyperemia two years ago, which did not receive treatment. The diagnosis of MMP was confirmed based on clinical examination, histopathology, and direct immunofluorescence. Treatment involved a stepped regimen of systemic glucocorticoids combined with immunosuppressants, underpinned by multidisciplinary management involving departments of oral medicine, ophthalmology, and endocrinology. Results: After 13 months of treatment, the oral lesions completely resolved, active ocular inflammation was effectively controlled, and symblepharon stabilized without progression. The systemic glucocorticoid dosage was successfully reduced to a maintenance dose of 6mg/d, creating conditions for subsequent ocular surgery. Conclusions: For high-risk MMP, early and accurate diagnosis is the prerequisite. An individualized, stepwise treatment strategy centered on systemic immunosuppression, with participation from multiple disciplines, is crucial for disease control, prevention of scar formation, and improvement of patient prognosis.

Key words: mucous membrane pemphigoid, ocular cicatricial pemphigoid, multidisciplinary team, glucocorticoids, immunosuppressants, individualized treatment